How Gene and CAR-T Therapies Are Changing the Cost of Employer Health Plans. Healthcare is entering a new era — one where certain diseases aren’t just managed, they’re potentially cured. For patients, this brings hope. For employers, however, it introduces a new level of financial risk.
Our Benefits Architecture: Understanding the Life of a Medical Claim series explores the journey of a medical claim through an employer’s benefits plan. After covering the fundamentals, we’re now turning to areas of the plan that can have the greatest financial impact, where rare or high-cost treatments create unique challenges and make proactive planning essential.
Traditional strategies that worked for chronic care or standard medical claims aren’t designed to handle treatments that cost upwards of $1 million per patient. Understanding what’s at stake and planning proactively has never been more important.
Gene therapies work by replacing or repairing defective genes, potentially curing diseases at their source rather than simply managing symptoms. CAR-T therapies, on the other hand, are personalized cancer treatments that modify a patient’s immune cells to attack tumors more effectively. Both approaches are revolutionary and highly specialized, requiring complex coordination between hospitals, specialty pharmacies, and care teams.
These therapies can be life-changing for patients, but they can also carry a significant financial impact for employers managing health plans. Unlike chronic medications such as insulin for diabetes, they are often one-time treatments with high upfront costs, but potentially lifelong benefits.
Gene therapies can range from $1 million to $4 million or more per treatment. CAR-T therapies, when you include hospital care, monitoring, and follow-up, can exceed $1 million per patient. These therapies can involve significant medical support, including longer hospital stays, intensive monitoring, and management of potentially high-cost complications.
As these therapies become more common, the number of patients eligible will grow, and what once was a rare-event claim could become a predictable component of plan spending.
For self-funded plans, the financial exposure is real and potentially catastrophic. A single high-cost claim can have ripple effects across the plan, creating budget unpredictability, affecting premiums, and disrupting stop-loss coverage, such as lasers, higher attachments, and renewal pressure.
These treatments are redefining financial risk for self-funded plans, with the potential for large, unpredictable claims that can quickly strain budgets and coverage structures. Below are examples of high-cost, high-impact therapies:
Gene Therapies
CAR-T Therapies
Many employers are adapting strategic ways to manage this extreme financial risk. One of the most common approaches is carving out the exposure by partnering with specialty carriers that handle high-cost therapies separately from the core plan, often through fixed per-employee-per-month (PEPM) costs. This structure helps protect against financial disruption while still providing access to life-changing treatments, similar to how many plans manage organ transplants.
At the same time, employers are placing greater focus on managing where and how care happens. These therapies are complex, and outcomes can vary significantly depending on how and where care is delivered. As a result, strategies such as steering patients to Centers of Excellence, leveraging specialized clinical navigation, and actively managing site-of-care decisions are becoming more common. Strong execution in this area can improve clinical outcomes and control unnecessary costs.
For therapies that remain within the plan, employers are taking a more deliberate approach to aligning with a stop-loss strategy. This means modeling worst-case scenarios, evaluating attachment point strategies, and understanding how even a single claim can influence renewal outcomes. Many employers are recognizing that this level of risk may not fit neatly within traditional stop-loss structures and are exploring alternative approaches to ensure adequate protection.
When it comes to these breakthrough therapies, the numbers can be staggering. As an employer or HR leader, it’s worth taking a step back and asking some hard questions:
Planning ahead, understanding your exposure, and establishing systems to manage these risks is essential for protecting your plan.
Gene and CAR-T therapies are just the beginning of a broader trend toward high-cost, potentially curative treatments. Employers who start conversations now can put themselves in the best position to provide life-changing treatments to their employees without jeopardizing their plans.
If you have questions about Gene and CAR-T therapies and your health plan, don’t hesitate to reach out. We are here to talk about it with you.
Cost figures, coverage details, and plan design elements presented in this blog are for illustrative purposes only and do not reflect any specific insurance policy or provider. Actual costs will vary based on your organization’s health plan, the insurance carrier, provider contracts, and the specifics of each medical situation. Employers and employees should refer to their official plan documents or speak with their broker or benefits consultant for guidance if needed.
Spring in Indiana means one thing for homeowners: storm season is here. From hail damage and…
The Million-Dollar Prescription: How Orphan Drugs Are Redefining Employer Risk. One employee, one prescription, and…
The $300,000 Difference: Managing the Cost of Specialty Drugs. It often starts with a diagnosis.…
Pharmacy Benefits Are Changing – Is Your Plan Ready? Many employer health plans appear financially…
Many people own valuable items without realizing their standard insurance policy may not fully protect them.…
Beyond the Coin Flip: Building Sustainable Healthcare in an Unpredictable Market. For many employers, healthcare…
